BIG
HUMA icon

Brooklyn Investment Group’s Humacyte HUMA Stock Holding History

Brooklyn Investment Group’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,338
Closed -$3.99K – 3360
2025
Q1 		$3.99K Buy
+2,338
New +$8.78K ﹤0.01% 1905

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Brooklyn Investment Group's HUMA Position: Q2 2025 in Review

Brooklyn Investment Group sold out of Humacyte (HUMA) in Q2 2025, closing a stake of 2,338 shares — an estimated $3.99K sold.

Brooklyn Investment Group first reported a position in HUMA in Q1 2025 and held it in 1 quarter. The position peaked at $3.99K in Q1 2025. 156 funds tracked by Wall St. Rank hold HUMA as of Q2 2025.

  • Brooklyn Investment Group reported no remaining Humacyte position as of Q2 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 2,338 Humacyte shares in Q2 2025, an estimated $3.99K.
  • Brooklyn Investment Group first reported a position in Humacyte in Q1 2025 and held it in 1 quarter.
  • Brooklyn Investment Group's Humacyte position peaked at $3.99K in Q1 2025.
  • 156 funds tracked by Wall St. Rank held Humacyte as of Q2 2025.

Based on Brooklyn Investment Group's 13F filing for Q2 2025, filed 12 Aug 2025.